Journal of thyroid disorders & therapy最新文献

{"title":"Screening study of iodine deficiency status and Thyroid diseases in caucasian children","authors":"S. Janjgava","doi":"10.4172/2167-7948.C1.001","DOIUrl":"https://doi.org/10.4172/2167-7948.C1.001","url":null,"abstract":"","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"05 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70842521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral Thyroid Agenesis Curiosity or Predictor of Future Pathology","authors":"J. Ker","doi":"10.4172/2167-7948.1000201","DOIUrl":"https://doi.org/10.4172/2167-7948.1000201","url":null,"abstract":"Unilateral thyroid agenesis (thyroid hemiagenesis) is a rare disorder with less than 300 cases currently in the world literature. The current clinical importance of this condition lies in the possibility that such patients may be at an increased risk for a wide range of future pathology in the contralateral lobe. If this indeed proves to be the case in future, these patients need to be identified. A case of incidentally discovered unilateral thyroid agenesis is presented and the clinical importance discussed.","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"5 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2016-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70841097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid Cancer Metabolism: A Review.","authors":"Kurren S Gill, Patrick Tassone, James Hamilton, Nikolaus Hjelm, Adam Luginbuhl, David Cognetti, Madalina Tuluc, Ubaldo Martinez-Outschoorn, Jennifer M Johnson, Joseph M Curry","doi":"10.4172/2167-7948.1000200","DOIUrl":"10.4172/2167-7948.1000200","url":null,"abstract":"<p><p>Metabolic dysregulation within the tumor microenvironment (TME) is critical to the process of tumorigenesis in various cancer types. Thyrocyte metabolism in papillary and anaplastic thyroid cancer, however, remains poorly characterized, and studies analyzing the role of multicompartment metabolism in thyrocyte oncogenesis are sparse. We present a review of the current knowledge on cellular metabolism in non-cancerous and cancerous thyroid tissues, focusing on the monocarboxylate transporters MCT1 and MCT4, and on a transporter of the outer mitochondrial membrane TOMM20. Understanding the metabolic phenotype of tumor cells and associated stromal cells in thyroid cancer can have profound implications on the use of biomarker staining in detecting subclinical cancer, imaging as it relates to expression of various transport proteins, and therapeutic interventions that manipulate this dysregulated tumor metabolism to halt tumorigenesis and eradicate the cancer. Future studies are required to confirm the prognostic significance of these biomarkers and their correlation with existing staging schemas such as the AGES, AMES, ATA and MACIS scoring systems.</p>","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34574064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Case of Mucoepidermoid Carcinoma of the Thyroid Gland","authors":"S. Obidike, F. Aftab","doi":"10.4172/2167-7948.1000199","DOIUrl":"https://doi.org/10.4172/2167-7948.1000199","url":null,"abstract":"Thyroid cancers (CA) account for about 0.4% of all CA deaths. It is thus very important to be able to determine the type of CA in view of the differing prognosis and possibility of the CA being a secondary from other glands like the Salivary gland. Mucoepidermoid CA is an extremely rare form of Thyroid CA and not much is known about its origin, disease course and treatment. While some think it originates from the Salivary gland, others believe it comes from Ultimobrachial body cell nests. It seems to be slow growing but it also has some metastatic properties. Generally, total thyroidectomy has been suggested as treatment due to lack of adequate information about the disease. The authors want to present a rare finding of Mucoepidermoid CA in a Thyroid lump.","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"5 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2016-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70841030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Role of Different Imaging Modalities with Emphasis on Fdg Pet/Ct in the Management of Well Differentiated Thyroid Cancer (WDTC).","authors":"Tuba Karagulle Kendi A,&nbsp;Shwetha Mudalegundi,&nbsp;Jeffrey Switchenko,&nbsp;Daniel Lee,&nbsp;Raghuveer Halkar,&nbsp;Amy Y Chen","doi":"10.4172/2167-7948.1000202","DOIUrl":"https://doi.org/10.4172/2167-7948.1000202","url":null,"abstract":"<p><strong>Background: </strong>Positron emission tomography/computed tomography is suggested to have a role in detection of iodine negative recurrence in well differentiated thyroid cancer. The aim of this study is to identify role of different imaging modalities in the management of well differentiated thyroid cancer.</p><p><strong>Methods: </strong>We reviewed 900 well differentiated thyroid cancer patients after post-thyroidectomy who underwent recombinant human thyroid stimulating hormone stimulated Sodium Iodide I 131 imaging. Out of 900 patients, 74 had positron emission tomography/computed tomography. Multivariate analysis was performed by controlling positron emission tomography/computed tomography, Sodium Iodide I 131 scan, neck ultrasonography, age, sex, primary tumor size, stage, histology, thyroglobulin. Patients were grouped according to results of Sodium Iodide I 131 scan and positron emission tomography/computed tomography.</p><p><strong>Results: </strong>Positron emission tomography/computed tomography was positive in 23 of 74 patients. The sensitivity for positron emission tomography was 11/11(100%), the specificity was 51/63 (81.0%), the positive predictive value was 11/23 (47.8%), and the negative predictive value was 51/51 (100%). The sensitivity for the neck ultrasonography was 4/8 (50%), the specificity was 53/60 (88.3%), positive predictive value was 4/11 (36.4%), and negative predictive value was 53/57 (93.0%). 50% of patients who had Sodium Iodide I 131 negative scan and positive positron emission tomography/computed tomography had a change in management. Thirty-six percent with positive neck ultrasonography had a change in management. Out of 11 recurrences, 6 had distant metastatic disease, and 5/11 had regional nodal disease. Neck ultrasonography showed nodal metastasis in 4/5 (80%).</p><p><strong>Conclusion: </strong>Positron emission tomography/computed tomography altered management in the presence of a high thyroglobulin level and a negative Sodium Iodide I 131 scan. Neck ultrasonography should be the first line of imaging with rising thyroglobulin levels. Positron emission tomography/computed tomography should be considered for cases with high thyroglobulin levels and normal neck ultrasonography to look for distant metastatic disease.</p>","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"5 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2167-7948.1000202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35405501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid Cancer: State of Art of in Morocco","authors":"Meryem Kaabouch, M. Mzibri, Al Kandry Siffeddine, R. A. E. Hassani, A. Bouzidi","doi":"10.4172/2167-7948.1000197","DOIUrl":"https://doi.org/10.4172/2167-7948.1000197","url":null,"abstract":"Thyroid cancer is the most frequent endocrine malignancy, and its worldwide increase incidence has been recently reported. However, both the cause of this alarming increase and its impact on the public health remain to be determined. In this review, we propose a brief update of thyroid cancer and its relevant risk factors in the light of new published data in the field. We also summarize data concerning the thyroid cancer in Morocco as well as its incidence. Finally, we propose some recommendations for a better management of thyroid cancer in Morocco.","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"13 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70841319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of BRAFV600E Mutation and Persistence of Papillary Thyroid Cancer after Total Thyroidectomy and Routine Central Neck Dissection","authors":"Feng Liu, Zhihui Li, Zhu Jingqiang, R. Gong, Wei Gao, Qian-qian Han, Tengfei Xing, Lin-gao He, Libo Yang, F. Ye","doi":"10.4172/2167-7948.1000198","DOIUrl":"https://doi.org/10.4172/2167-7948.1000198","url":null,"abstract":"Purpose The aim of this study is to investigate the predictive value of BRAF V600E mutation for the persistence of papillary thyroid cancer (PTC) after total thyroidectomy and routine central neck dissection. Patients and Methods We collect the clinicopathological data of 288 PTC patients with total thyroidectomy (TT) and routine central neck dissection (CND), and analyzed the relationship between BRAFV600E mutation status and the rate of elevated non-stimulated thyroglobulin (NSTg) value. And we also collect the clinicopathological data of 370 PTC patients who needed radio iodine ablation(RIA) after TT and routine CND, and analyzed the relationship between BRAFV600E mutation status and the rate of elevated stimulated Tg (STg)value before RIA. The clinicopathological data included gender, age at diagnosis, multifocality, bilaterality, tumor size, extrathyroidal invasion, and lymph node status of these patients. All the patents were diagnosis as PTC before operation by the combination with ultrasonograph and FNA (fine needle asperation). Results BRAFV600E mutation is not associated with the elevated rate of elevated Tg value after TT and routine CND. Conclusions BRAF V600E mutation is not an independent predictive factor for the persistence of papillary thyroid cancer (PTC) after TT and routine CND.","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"5 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70841428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower Starting Dose of Sorafenib for Thyroid Cancer : A Case Report andLiterature Review","authors":"Eun Mi Lee, Ju Won Lee, Jun Yeob Lee, B. Kim","doi":"10.4172/2167-7948.1000196","DOIUrl":"https://doi.org/10.4172/2167-7948.1000196","url":null,"abstract":"Since the FDA approved sorafenib use for thyroid cancer, administration of this medicine to thyroid-cancer patients had steadily increased. However, an appropriate starting dose for this treatment has not been established, which is problematic because the sorafenib discontinuation rate due to toxicity is higher among thyroid cancer patients than among patients with other solid tumors. We recently treated a papillary thyroid cancer patient who experienced a dramatic improvement after being treated with a 400-mg starting dose of sorafenib. Herein, we describe this case and discuss its implications for an appropriate sorafenib starting dose for thyroid cancer.","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"4 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2015-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70841244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypothyroidism: Another Risk Factor for the Development of Diabetes in an Already Vulnerable Asian Indian Population?","authors":"A. Bhargava, S. Waghdhare, S. Siddiqui, Kunal Srivastava, S. Jha","doi":"10.4172/2167-7948.1000E125","DOIUrl":"https://doi.org/10.4172/2167-7948.1000E125","url":null,"abstract":"Recently, Gronich et al. published a wonderful study postulating several molecular mechanisms that may explain the complex interplay between hypothyroidism, subclinical hypothyroidism, and statin use vis-a-vis the development of diabetes mellitus (DM), and elucidated this in clinical practice. Hypothyroidism was found to carry an increased risk for developing new-onset DM in both the statin (RR 2.06 [95% CI 1.42–2.99]) and the non-statin (RR 1.66 [95% CI 1.05– 2.64]) cohort. On the other hand, subclinical hypothyroidism seemed to only factor in the development of DM in patients on a statin (RR 1.94 [95% CI 1.13–3.34]), as opposed to those not on a statin (RR 1.20 [95% CI 0.52–2.75]). Although over 90% of the participants in this study were of Jewish ethnicity, a multivariate analysis calculated Arab ethnicity as having a RR of 1.50 (95% CI 1.40–1.62) for developing DM associated with statin use and thyroid disease [1].","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"4 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2015-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70842405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-differentiation of Conventional Papillary Thyroid Carcinoma into Squamous Cell Carcinoma","authors":"M. Hararah, Ryan Gertz, R. Sippel, Aaron M. Wiel","doi":"10.4172/2167-7948.1000192","DOIUrl":"https://doi.org/10.4172/2167-7948.1000192","url":null,"abstract":"Primary squamous cell carcinoma (SCC) of the thyroid is an extremely rare entity comprising less than 1% of thyroid malignancies [1]. It has been associated with the tall-cell variant of papillary thyroid carcinoma (PTC) [2-5]. It is theorized that SCC of the thyroid may arise from de-differentiation of more common thyroid carcinomas. Here, we present a unique case of SCC of the thyroid gland arising in the background of classic PTC with primary site and regional nodal disease demonstrating both histologies. Similar transformations involving the tall cell variant of PTC and spindle cell carcinoma were noted to be particularly aggressive [2-4]. However, little is known about its pathogenesis and disease prognosis. This study was exempt by the University of Wisconsin, Madison Institutional Review Board.","PeriodicalId":91565,"journal":{"name":"Journal of thyroid disorders & therapy","volume":"4 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2015-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70841059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}